ClinicalTrials.gg

TargetBeta

IL17A

interleukin 17A · also IL-17A, IL-17, CTLA8, IL17 · Interleukins

8 programs in company-led studies act on IL17A, from 7 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
secukinumabruleNovartisphase 41284 running–NCIt
vunakizumabruleJiangsu HengRui Medicinephase 4174 running–ChEMBL
ixekizumabruleEli Lillyphase 4383 running–ChEMBL
bimekizumabruleUCBphase 3437 runningIL17FChEMBL
sonelokimabruleMoonLake Immunotherapeuticsphase 3124 runningIL17FChEMBL
SCT650CruleSinocelltech Groupphase 233 running–the studies' text
tibulizumabruleEli Lillyphase 252 runningTNFSF13BChEMBL
UA026ruleUsynova Pharmaceuticalsphase 111 running–the studies' text

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.